comparemela.com
Home
Live Updates
Ignacio Melero Center - Breaking News
Pages:
Latest Breaking News On - Ignacio melero center - Page 1 : comparemela.com
CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of
Kostenloser wertpapierhandel
Catalym gmb
Phil lhuillier
Ignacio melero center
World health organization
International nonproprietary name
Trophic communications
Differentiation factor
Ted human effector
Ignacio melero
Advanced medical research
Principal investigator
Eugen leo
Chief medical officer
Phill huillier
Growth differentiation
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
Press release content from Business Wire. The AP news staff was not involved in its creation.
Catalym gmb
Phil lhuillier
Ignacio melero center
World health organization
International nonproprietary name
Trophic communications
Differentiation factor
Ignacio melero
Advanced medical research
Principal investigator
Eugen leo
Chief medical officer
Phill huillier
Growth differentiation
Laura mittmann
Catalym gmbh
vimarsana © 2020. All Rights Reserved.